Results 41 to 50 of about 3,067,072 (318)

Examining the Safety Profile of Janus Kinase (JAK) Inhibitors in the Management of Immune-Mediated Diseases: A Comprehensive Review

Life, 2023
Janus kinase (JAK) inhibitors have heralded a paradigm shift in the management of immune-mediated diseases. While their efficacy is well-established, the safety concerns associated with these agents, particularly regarding thromboembolic events (TE ...
Krasimir Kraev, Mariela Gencheva Geneva-Popova, Bozhidar Krasimirov Hristov, Petar Angelov Uchikov, Stanislava Dimitrova Belova-Popova, Maria Ilieva Kraeva, Yordanka Mincheva Basheva-Kraeva, Nina Staneva Stoyanova, Vesela Todorova Mitkova-Hristova, Maria Stoyanova Koleva-Ivanova, Daniela Ivova Taneva, Atanas Slavchev Ivanov   +11 more
doaj   +1 more source

Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis

Frontiers in Immunology, 2023
Background Alopecia areata (AA) is an immune disease characterized by non-scarring hair loss. With the widespread application of JAK inhibitors in immune-related diseases, attention is being given to their role in the treatment of AA.
Dong-fang Wei, Yi Chen, Yuqing Shen, Bo Xie, Xiuzu Song   +4 more
semanticscholar   +1 more source

JAK inhibitors disrupt T cell-induced proinflammatory macrophage activation [PDF]

, 2023
Objectives: Macrophage subsets, activated by T cells, are increasingly recognised to play a central role in rheumatoid arthritis (RA) pathogenesis. Janus kinase (JAK) inhibitors have proven beneficial clinical effects in RA.
Nijjar, Jagtar Singh, Porter, Duncan, Goodyear, Carl S, McInnes, Iain B, Nyirenda, Mukanthu H., Gilchrist, Derek S, Frleta-Gilchrist, Marina, Gilchrist, Derek S., McInnes, Iain B., Siebert, Stefan, Nyirenda, Mukanthu H, Goodyear, Carl S.   +11 more
core   +1 more source

Janus-kinase Inhibitors in Pathogenesis and Management of Chronic Urticaria: A Review of the Literature [PDF]

Journal of Pediatrics Review, 2023
Background: Chronic urticaria is a long-lasting condition, sometimes with serious comorbidities, severely affecting the quality of life, which makes the patients seek efficient therapies to achieve sustained remissions.
Sepideh Darougar, Seyed Karen Hashemitari, Sara Montazeri Namin   +2 more
doaj  

JAK inhibitors: Ten years after

European Journal of Immunology, 2021
AbstractThe European Journal of Immunology was launched 50 years ago, coinciding with the discovery of many cytokines and growth factors and the emergence of an entirely new field of research. Ultimately, our knowledge about the biological activity of these factors allowed us to better understand how the immune system functions in the context of ...
Spinelli, Francesca Romana, Meylan, Françoise, O'Shea, John J., Gadina, Massimo   +3 more
openaire   +5 more sources

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration

Annals of the Rheumatic Diseases, 2022
Background JAK-inhibitors (JAKi), recently approved in rheumatoid arthritis (RA), have changed the landscape of treatment choices. We aimed to compare the effectiveness of four current second-line therapies of RA with different modes of action, since ...
K. Lauper, M. Iudici, D. Mongin, S. Bergstra, D. Choquette, C. Codreanu, R. Cordtz, D. De Cock, L. Dreyer, O. Elkayam, E. Hauge, D. Huschek, K. Hyrich, F. Iannone, N. Inanç, L. Kearsley‐Fleet, E. Kristianslund, T. Kvien, B. Leeb, G. Lukina, D. Nordström, K. Pavelka, M. Pombo-Suárez, Ž. Rotar, M. Santos, Anja Strangfeld, P. Verschueren, D. Courvoisier, A. Finckh   +28 more
semanticscholar   +1 more source

In-Silico Approach for Identification of The Most Potent JAK Inhibitors as a Possible Treatment for Myelofibrosis

, 2023
Background: Myelofibrosis is a type of malignancy that is mainly caused by JAK2 gene mutation. This study employed an in silico approach to analyse the binding affinity of five JAK2 inhibitors that were already FDA-approved in order to determine the most
Ellen, Budiono, Kelly, Nadya, Natasya Irene, Santoso, arli aditya, parikesit, Celine, Yeo, Aurelia, Catherine, Danita Sherry, Kristi, Stephanie Grace , Mᴀʀɪɴɢᴋᴀ   +7 more
core   +1 more source

Molecular dissection of Janus kinases as drug targets for inflammatory diseases

Frontiers in Immunology, 2022
The Janus kinase (JAK) family enzymes are non-receptor tyrosine kinases that phosphorylate cytokine receptors and signal transducer and activator of transcription (STAT) proteins in the JAK-STAT signaling pathway.
Sunghark Kwon
doaj   +1 more source

A multitask GNN-based interpretable model for discovery of selective JAK inhibitors

Journal of Cheminformatics, 2022
The Janus kinase (JAK) family plays a pivotal role in most cytokine-mediated inflammatory and autoimmune responses via JAK/STAT signaling, and administration of JAK inhibitors is a promising therapeutic strategy for several diseases including COVID-19 ...
Yimeng Wang, Yaxin Gu, Chaofeng Lou, Yuning Gong, Zengrui Wu, Weihua Li, Yun Tang, Guixia Liu   +7 more
doaj   +1 more source

Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition

Pharmacology Research & Perspectives, 2019
Janus kinase (JAK) inhibitors have emerged as an effective class of therapies for various inflammatory diseases such as rheumatoid arthritis (RA). JAK inhibitors function intracellularly by modulating the catalytic activity of JAKs and disrupting the ...
Martin E. Dowty, Tsung H. Lin, Michael I. Jesson, Martin Hegen, David A. Martin, Vaibhav Katkade, Sujatha Menon, Jean‐Baptiste Telliez   +7 more
doaj   +1 more source